

HOSC UHL CANCER UPDATE SEPTEMBER 2020




Key achievements

- Increasing referral numbers
- Robust harm review process in place
- Clinical contact maintained with all patients
- All patients categorised against 4 priority scores ensuring most urgent are seen first
- All pathways reviewed and updated in line with National and Society guidance released during COVID
- Improved performance
- Pre COVID 62 day performance achieved
- Target of 20% reduction in 62 day backlog in 6 weeks set by NHSI/E achieved
- Decrease in 62 day backlog to pre COVID levels
- Decrease 104 day backlog
- Review of Rapid actions with all tumour sites to enable further recovery



2 WW Referral Recovery

Caring at its best









- Referrals have continued to rise month on month since April 2020.
- Currently approximately 200 a month below the same period last year.
- Fast tracked approval for NSS programme (funded by EMCA) currently seconding to posts with an aim to start in November. This will help pick up any patients that may have been delayed during COVID.
- We continue to communicate to the public and to primary care that cancer services are BAU and the measures we have taken to ensure we have done everything possible to reduce the COVID risk.

One team shared values



2WW Recovery by tumour site











Is
er
ist

32

One team shared values



2WW Recovery by tumour site




33

One team shared values



62 Day recovery

University Hospitals



| Tumour Site | Target Non Adjusted | Actual | Trend |
|-----------------------|---------------------|--------|-----------|
| Haematology | 0 | 1 | Green |
| HPB | 2 | 5 | Yellow |
| H&N | 4 | 9 | Yellow |
| Lower GI | 6 | 15 | Green |
| Upper GI | 1 | 8 | Green |
| Urology | 15 | 41 | Red |
| Skin | 1 | 2 | Green |
| Breast | 2 | 9 | Green |
| Sarcoma | 0 | 0 | Yellow |
| Lung | 8 | 3 | Yellow |
| Gynae | 8 | 6 | Red |
| Other (eg CUP, Brain) | 0 | 1 | Red |
| | | | 34 |


Backlog week ending 28th Aug. Trend based on previous week's position, amber = no change.

- Significant reduction in backlog due to CMG prioritisation and focus as well as a reduction in referrals during COVID
- The backlog is at pre COVID levels and we aim to decrease further where possible
- Delays include patient choice, process delays and capacity delays; all of which are being actioned to decrease delays where possible

One team shared values



104 Day recovery



| Service | LLR | Tertiary | Patients with a treatment date confirmed |
|-------------|-----|----------|--|
| Breast | 3 | 1 | 1 |
| Lower GI | 1 | 0 | 0 |
| Head & Neck | 0 | 0 | 0 |
| Lung | 0 | 0 | 0 |
| HPB | 2 | 0 | 0 |
| Haematology | 1 | 0 | 0 |
| Skin | 0 | 0 | 0 |
| Upper GI | 0 | 0 | 0 |
| Urology | 14 | 3 | 7 |

Data for week ending 28.8.20

35

- 104 days excluding consultant upgrades split for LLR and Tertiary patients by tumour site
- Of the 25 patients, 10 have a confirmed diagnosis
- Of the remaining 15 patients without a diagnosis, 3 have TCI dates with the remaining either in the diagnostic phase or delayed pathways due to patient choice.
- There are 4 tertiaries in the 104 day backlog
- RAG rating added to indicate trend based on previous weeks reporting
- Daily updates, actions and chases led by DOI are in place for patients over 90 days

One team shared values



June Performance






University Hospitals
of Leicester

NHS Trust

Caring at its best

| Standard | Target | Position | Pts treated within target | Pt treated outside target |
|-----------------------------------|--------|----------|---------------------------|---------------------------|
| 2WW | 93% | 92.1% | 2253 | 194 |
| 2WW Breast | 93% | 96.3% | 236 | 9 |
| 31 Day 1 st Treatments | 96% | 89.7% | 338 | 39 |
| 31 Day SUB Surgery | 94% | 70.5% | 67 | 28 |
| 31 Day DRUGS | 98% | 98.9% | 93 | 1 |
| 31 Day Radiotherapy | 94% | 94.4% | 101 | 6 |
| 62 Day | 85% | 70.6% | 151.5 | 63 |
| 62 Day Screening | 90% | 0.0% | 0 | 15 |
| 28 Day FDS 2WW | 75% | 83.2% | 1863 | 376 |
| 28 Day FDS Breast 2WW | 75% | 99.6% | 237 | 1 |
| 28 Day FDS Screening | 75% | 2.6% | 1 | 37 |



One team shared



July and August predicted performance

Caring at its best

| Standard | Target | SCR Position | |
|-----------------------------------|--------|--------------|--------|
| | | July | August |
| 2WW | 93% | 89.7% | 89.2% |
| 2WW Breast | 93% | 97.7% | 94.3% |
| 31 Day 1 st Treatments | 96% | 91.4% | 88.1% |
| 31 Day SUB Surgery | 94% | 68.9% | 69% |
| 31 Day DRUGS | 98% | 100% | 100% |
| 31 Day Radiotherapy | 94% | 100% | 98.9% |
| 62 Day | 85% | 71.5% | 70.1% |
| 62 Day Screening | 90% | 0 | 25% |
| 62 Day Consultant Upgrades | N/A | 80% | 86.1% |
| 28 Day FDS 2WW | 75% | 83.8% | 81.6% |
| 28 day FDS Screening | 75% | 31% | 78.8% |
| 28 Day FDS Breast | 75% | 99.2% | 96.5% |

- Data as of week ending 28.8.20
- Non validated position and is subject to change
- Screening programmes have restarted
- IS and Alliance being used as a priority for Cancer and urgent patients that meet their criteria (diagnostic and treatment)
- Chemotherapy and Radiotherapy are managing capacity
- Surgical capacity and endoscopy decreased due to COVID restrictions, but is recovering

One team shared values



Transformation

- Transformation programme (against strategy) has been on hold during COVID
- Transformation as a result of COVID
 - Telephone appointments
 - Pathway changes eg decrease fraction times and frequency in radiotherapy
 - Capsule endoscopy
 - Use of hormones
- NSS plan

